Ascentage Pharma (6855.HK), a prominent global biopharmaceutical firm, recently unveiled the latest preclinical study results for its innovative drug candidates at the American Association of Cancer Research Annual Meeting (AACR 2024) held in San Diego, California. This pivotal revelation underscores the company’s continued dedication to pioneering novel therapies for cancer, chronic hepatitis B (CHB), and […]
Immutep Limited, an Australian biotech company specializing in LAG-3 immunotherapies for cancer and autoimmune diseases, has partnered with Charles River Laboratories to conduct a GLP toxicology study for its preclinical candidate, IMP761, targeting autoimmune diseases. Developed as a first-in-class LAG-3 agonist antibody, IMP761 aims to address the root cause of autoimmune diseases by mitigating the […]
Labcorp, an American testing laboratories company, said that its board of directors has authorized it to undertake a spin-off of its fully-owned clinical development business to its shareholders via a tax-free deal. The proposed spin-off will result in a couple of standalone, publicly traded firms, which will be Labcorp, a global laboratory business, and the […]
X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases and cancer. This strategic move unites two Massachusetts-based companies, with X4 Pharmaceuticals specializing in immune cell trafficking therapies for conditions such as primary immunodeficiencies and cancer, and Arsanis leading the charge in monoclonal antibody (mAb) immunotherapies for […]